UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001758
Receipt number R000002115
Scientific Title The efficacy of cyclospolin A and low dose mycophenolate mofetil to prevent GVHD for reduced-intensity (fludarabine , cyclophosphamide , total body irradiation) cord blood stem cell transplantation
Date of disclosure of the study information 2009/03/06
Last modified on 2009/03/05 19:57:12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The efficacy of cyclospolin A and low dose mycophenolate mofetil to prevent GVHD for reduced-intensity (fludarabine , cyclophosphamide , total body irradiation) cord blood stem cell transplantation

Acronym

The efficacy of cyclospolin A and low dose mycophenolate mofetil to prevent GVHD for reduced-intensity(FLU,CY,TBI) cord blood stem cell transplantation

Scientific Title

The efficacy of cyclospolin A and low dose mycophenolate mofetil to prevent GVHD for reduced-intensity (fludarabine , cyclophosphamide , total body irradiation) cord blood stem cell transplantation

Scientific Title:Acronym

The efficacy of cyclospolin A and low dose mycophenolate mofetil to prevent GVHD for reduced-intensity(FLU,CY,TBI) cord blood stem cell transplantation

Region

Japan


Condition

Condition

Hematologic malignancies

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

The safety and efficacy of cyclospolin A and mycophenolate mofetil to prevent GVHD for reduced-intensity ( FLU , CY , TBI ) cord blood stem cell transplantation .

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Non relapse mortality on day 100 post transplantaion

Key secondary outcomes

1)Incidence and severity of acute GVHD
2)Incidence of hepatic veno-occlusive disease and thrombotic microangiopathy
3)Incidence of infectious disease
4)Disease-free survival and overall survival rate at 1 year and 2 years after transplantation
5)Engraftment rate 100 days after transplantation
6)Time to hematopoietic recovery


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Intravenous injection of fludarabine (30mg/m2/day, for 6 days) and cyclophosphamide (50mg/kg/day,once)
Use cyclospolin A and mycophenolate mofetil ( for 30 days) as a GVHD prophylaxis

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Diagnosis as hematological malignancy
2) Unavailability of HLA matched- related or unrelated donor , or needs urgent transplantation.
3) Availability of CB uint
4)As inappropriate requirements for myeloablative conditioning, satisfy one of the following criteria.
a) Aged over 50 years
b)Impaired organ function
c)Previous stem cell transplantation (except re-transplantaion with CB unit ,but the entry is once.)
5) Written informed consent

Key exclusion criteria

1) Double cancer
2) Sever mental disease
3)Seropositive to HIV
4) History of adverse reaction for the agents included in the protocol in conditioning (fludarabine, cyclophosphamide), in GVHD prophylaxis (Cyclosporine A, mycophenolate mofetil)
5) Pregnant or lactating women
6)Inadequate to entry judged by investigators.

Target sample size

57


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hideki Kodo

Organization

Tokyo Cord Blood Bank

Division name

Tokyo Cord Blood Bank

Zip code


Address

1-16-19,Higashi-Yotugi,Katsushika-Ku,Tokyo,Japan

TEL

03-5671-3510

Email



Public contact

Name of contact person

1st name
Middle name
Last name Hideki Kodo

Organization

Tokyo Cord Blood Bank

Division name

Tokyo Cord Blood Bank

Zip code


Address

1-16-19,Higashi-Yotugi,Katsushika-Ku,Tokyo,Japan

TEL

03-5671-3510

Homepage URL


Email



Sponsor or person

Institute

RICBT Study Group

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2009 Year 03 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Date of protocol fixation

2008 Year 09 Month 01 Day

Date of IRB


Anticipated trial start date

2008 Year 10 Month 01 Day

Last follow-up date

2012 Year 09 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2009 Year 03 Month 05 Day

Last modified on

2009 Year 03 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002115


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name